Lung Cancer Clinical Trial
Official title:
A Smart Self-Management Support Programme (3S) to Improve Quality of Life in Patients With Lung Cancer - A Pragmatic Randomized Controlled Trial With Mixed-method Evaluation
Lung cancers patients often experience multiple symptoms (e.g. fatigue, dyspnea, distress, depression, sleep disturbance). The current study attempts to explore the efficacy of the Smart Self-Management Support Programme (3S) in improving quality of life of patients using self-management support programme with mobile devices.
Status | Not yet recruiting |
Enrollment | 320 |
Est. completion date | June 30, 2026 |
Est. primary completion date | March 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Patients: Inclusion Criteria: - Aged 18 years or above - Diagnosis of advanced-stage (stage III or stage IV) non-small cell lung cancer - Ambulatory and capable of all self-care activities (ECOG =2) - Either undergoing or has finished oncology therapy - Mentally, cognitively and physically fit to join as determined by the doctor in charge and responsible clinical investigators - Can speak and read Chinese - Willing to complete the patient-reported outcome questionnaire - Has a smartphone with WhatsApp or WeChat Exclusion Criteria: - Preparing for lung operation - Skeletal fragility - Serious active infection - Inability to walk - Previously untreated symptomatic brain metastases - Severe respiratory insufficiency - Uncontrolled pain - Diagnosed psychiatric illness with or without medication Family Caregivers: Inclusion criteria: - Aged 18 years or above - Family caregivers of recruited patients Exclusion criteria: - Unable to speak and read Chinese - Unwilling to complete the patient-reported outcome questionnaire |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Queen Mary Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong | Queen Mary Hospital, Hong Kong, The Queen Elizabeth Hospital, United Christian Hospital |
Hong Kong,
Hernandez Silva E, Lawler S, Langbecker D. The effectiveness of mHealth for self-management in improving pain, psychological distress, fatigue, and sleep in cancer survivors: a systematic review. J Cancer Surviv. 2019 Feb;13(1):97-107. doi: 10.1007/s11764-018-0730-8. Epub 2019 Jan 11. — View Citation
Ji W, Kwon H, Lee S, Kim S, Hong JS, Park YR, Kim HR, Lee JC, Jung EJ, Kim D, Choi CM. Mobile Health Management Platform-Based Pulmonary Rehabilitation for Patients With Non-Small Cell Lung Cancer: Prospective Clinical Trial. JMIR Mhealth Uhealth. 2019 Jun 21;7(6):e12645. doi: 10.2196/12645. — View Citation
Kondylakis H, Bucur A, Crico C, Dong F, Graf N, Hoffman S, Koumakis L, Manenti A, Marias K, Mazzocco K, Pravettoni G, Renzi C, Schera F, Triberti S, Tsiknakis M, Kiefer S. Patient empowerment for cancer patients through a novel ICT infrastructure. J Biomed Inform. 2020 Jan;101:103342. doi: 10.1016/j.jbi.2019.103342. Epub 2019 Dec 6. — View Citation
Saetan P, Chaiviboontham S, Pokpalagon P, Chansriwong P. The Effects of the Respiratory Rehabilitation Program on Perceived Self-Efficacy and Dyspnea in Patients with Lung Cancer. Asian Nurs Res (Korean Soc Nurs Sci). 2020 Dec;14(5):277-285. doi: 10.1016/j.anr.2020.08.010. Epub 2020 Sep 8. — View Citation
Zhu X, Han S, Chu H, Wang M, Chen S. Influence of self-management exercise intervention on the cancer related fatigue severity and self-management efficacy of patients with non-small cell lung cancer after operation. J Pak Med Assoc. 2020 Sep;70 [Special Issue](9):88-93. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in health-related quality of life | Measured by a 30-item European Organization for Research and Treatment of Cancer and Lung Module. All scale scores are linearly converted to a range from 0 to 100. Higher scores indicate better functioning and quality of life. | Baseline and 8-week follow-up | |
Secondary | Change in health-related quality of life | Measured by a 30-item European Organization for Research and Treatment of Cancer and Lung Module. All scale scores are linearly converted to a range from 0 to 100. Higher scores indicate better functioning and quality of life. | Baseline and 24-week follow-up | |
Secondary | Change in patient activation | Measured by a 13-item Patient Activation Measure with a 5-point Likert response scale from 0 to 4. Raw scores are transformed to a scale of 0-100 with higher scores indicating a higher activation in self-management. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in general self-efficacy | Measured by a 10-item General Self-efficacy Scale with a 4-point Likert response scale from 1 to 4, the total score ranges between 10 and 40, with a higher score indicating more self-efficacy. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in acceptance of illness | This is measured by a 12-item Peaceful Acceptance subscale of the Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire. Each item ranges between 1 and 4. A higher score indicates a greater extent of acceptance of the cancer diagnosis. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in physical activity level | Measured the days and duration of physical activity level (light, moderate and vigorous) and sitting time in the past 7 days by the International Physical Activity Questionnaire (short version) with 4 questions. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in diet habit | Measured by 10-item dietary intake and practice outcome based questions | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in smoking and drinking habits | Measured by self-reported drinking and smoking frequency | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in health status | Measured by 5-item EuroQol-5D Questionnaire. Each item is a different dimension that ranges from level 1-5, a higher level indicates a more severe level of perceived problem of that dimension. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in anxiety symptoms of patients | Measured by a 7-item Generalised Anxiety Disorder Assessment. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 21. The higher scores the greater severity of anxiety symptoms. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in depression symptoms of patients | Measured by a 9-item Patient Health Questionnaire. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 27. The higher scores the greater severity of depression symptoms. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in social and family support | Measured by 8-item Family and Friend Subscales of Multidimensional Scale of Perceived Social Support with a 7-point Likert scale. Each scale ranges from 4 to 28. A higher score equates with higher social support. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in adherence to agreed preset health-related goals | Measured by web-based platform (WhatsApp) in which patients will be asked to self-report whether they have completed their previously agreed health-related or general hygiene goals with nurses on a weekly basis. Adherence will be assessed by the frequency of self-reported goal completion by patients. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in symptom severity | Measured by 13-item European Organization for Research and Treatment of Cancer on symptom severity with a 4-point Likert scale. A higher score indicates a higher level of symptom severity. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in functional exercise capacity | Measured by a 6-minute walk test. The distance of participant walked with the instructions to walk back and forth at their own pace to a designated spot for 6 minutes. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in lower limb strength | Measured by a 30-second chair stand test. The number of participant stood up repeatedly from a chair for 30 seconds. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in hand grip strength | Measured by a dynamometer | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in flexibility | Measured by a Chair sit and reach test. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in balance | Measured by a single-leg stance test | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in body composition | Calculated by ratio of body weight and body height | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in objective physical activity level | Measured by a 7-day waist-worn accelerometer | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in objective sleep quality | Measured by a sleep-wake monitor (Motionlogger MicroWatch) | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in burden of family caregivers (For FCGs) | Measured by the 24-item Caregiver Burden Inventory with a 5-point Likert scale from 0 to 4. Total score ranges from 0 to 96 with higher score indicating a higher caregiver burden. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in quality of life of family caregivers (For FCGs) | Measured by the 35-item Caregiver Quality of Life Index-Cancer scale with a 5-point Likert scale from 0 to 4. Total score ranges from 0 to 140. Higher score indicates a higher quality of life. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in anxiety symptoms of family caregivers (For FCGs) | Measured by a 7-item Generalised Anxiety Disorder Assessment. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 21. The higher scores the greater severity of anxiety symptoms. | Baseline, 8-week and 24-week follow-up | |
Secondary | Change in depression symptoms of family caregivers (For FCGs) | Measured by a 9-item Patient Health Questionnaire. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 27. The higher scores the greater severity of depression symptoms. | Baseline, 8-week and 24-week follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|